An observational study in Leukemia, Leukemia, Lymphoblastic and Lymphoma, Large B-Cell, Diffuse, sponsored by AIDS Malignancy Consortium. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by AIDS Malignancy Consortium · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 168 open to participants now, 274 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 119th largest by enrollment of the 154 observational ones that give a count, is one of 36 that started in 2021, is one of 155 observational ones, and was the 1,417th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →168 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Wake Forest University Health Sciences · Sites in United States
Ages 18+
St. Jude Children's Research Hospital · Sites in United States
Ages 8+ · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States
Ages 1–25
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,545 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 653 · Phase 2 593 · Phase 3 107 · Phase 4 10
First in 1984; this study’s year is marked. 36 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 107 across 401 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 35 across the 1,269 interventional studies, 110 across the 154 observational. Of the 1,181 that completed or were terminated, 438 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 1,545 have an industry lead sponsor. The 10 most frequent:
AIDS Malignancy Consortium is the lead sponsor of 61 studies on the registry; 9 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
AIDS Malignancy Consortium has 1 study filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
95 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03020030Phase 3Dana-Farber Cancer InstituteTreatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | 2026-11-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04851717Phase 3Acacia Pharma LtdInvestigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | 2027-10 |
| NCT03104491Leland MethenyInotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
Add all 95 to your calendar (.ics) → With an account.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This protocol will develop an observational cohort of PLWH who have been or are being treated with CAR19 therapy outside of an AMC clinical trial. Following regulatory approval of this protocol, sites will be asked to capture information of participants, who carry a diagnosis of HIV disease AND received CAR19 therapy outside of a clinical trial between August 30, 2017 and August 30, 2023. Data captured will include data points are available as part of standard of care for participants undergoing CAR19 therapy. AMC investigators, as well as non-AMC investigators will identify eligible participants to the CIBMTR, who in turn will provide the AMC statistical center with de-identified data
Two landmark trials have led to the FDA approval of two different CD19 directed chimeric antigen receptor (CAR) T cell (CAR19) products in the United States for the treatment of relapsed or refractory (RR) large B-cell lymphoma after two or more lines of systemic therapy: tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta ®). In the ZUMA-1 registration trial for axicabtagene ciloleucel (axi-cel), 42% of the 101 treated patients achieved a complete response (CR), and with a median follow up of 15 months, the projected 1year progression free survival (PFS) was 70%. In a recent updated analysis, the CR rate was 58% with about 40% of patients having durable remissions at 2 years of follow up. Similar results were seen in the JULIET registrational trial for tisagenlecleucel (tisa-cel) with an overall response rate (ORR) of 52%, and a CR rate of 40% in the 93 patients evaluable for response; with a median follow up of 14 months, the estimated 12-months relapse-free survival was 65% (79% among patients with a CR). Tisagenlecleucel is also approved for the treatment of acute B-lineage lymphoblastic leukemia in patients up to the age of 25 years. Unfortunately, in both trials patients with known HIV infection were excluded. Therefore, no safety or efficacy data for treatment with CAR19 in PLWH exists, and access for PLWH in the US to this potentially curative treatment has been limited.
This has to be contrasted with the fact that malignancies, and specifically lymphomas, remain a major contributor to early mortality in PLWH. With a lifetime risk of cancer ranging between 24-40%, the leading cause of death in PLWH in economically developed countries is cancer, and the most common cancer in PLWH in the US remains Non-Hodgkin lymphoma (NHL). While early during the HIV epidemic, outcomes for PLWH and aggressive B-cell lymphomas were significantly worse compared to immunocompetent patients, this is no longer the case for the majority of PLWH, owing mainly to effective antiretroviral therapies leading to better tolerance of myelosuppressive chemotherapy and a consequent paradigm shift in aggressive therapies for HIV-associated lymphoma. It has been repeatedly demonstrated that PLWH have been able to safely tolerate aggressive high-dose chemotherapy, as well as autologous and even allogeneic hematopoietic cell transplant.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
This study's enrollment of 35 is below the median of 107 across 401 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →AIDS Malignancy Consortium is the lead sponsor of 61 studies on the registry; 9 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
Compared within Precursor Cell Lymphoblastic Leukemia-Lymphoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
People living with HIV treated with CD19-directed CAR T cell therapy for B-cell lymphoid malignancies
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinical information on participants, who carry a diagnosis of HIV disease AND received CAR19 therapy outside of a clinical trial between August 30, 2017 and August 31, 2021 will be captured
Rate of Toxicities Related to CAR19 Therapy
Toxicities related to CAR19 therapy will be reported by Common Terminology for Adverse Events (CTCAE) criteria, as well as American Society for Transplantation and Cellular Therapy (ASTCT) criteria (for cytokine release syndrome). Maximum neurotoxicity will be reported. Grade 1 indicates a mild adverse event; Grade 2 indicates a moderate adverse event; Grade 3 indicates a severe adverse event; Grade 4 indicates life-threatening adverse event; and Grade 5 indicates death.
Time frame: 12 months
Overall Response
Overall response is defined as complete remission (CR) plus partial remission (PR) based on response assessment using the Lugano criteria.
Time frame: 3 months and 6 months
Complete Remission
Complete remission is defined as complete disappearance of all disease based on response assessment using the Lugano criteria.
Time frame: 3 months
CD8 Count at 3 Months Post CAR-T
CD8 count measured at 3 months post CAR-T will be reported
Time frame: 3 months post CAR-T
CD8 Count at 6 Months Post CAR-T
CD8 count measured at 6 months post CAR-T will be reported.
Time frame: 6 months post CAR-T
CD8 Count at 9 Months Post-CAR T
CD8 count measured at 9 months post CAR-T will be reported.
Time frame: 9 months post-CAR T
CD8 Count at 12 Months Post-CAR T
CD8 count measured at 12 months post CAR-T will be reported.
Time frame: 12 months post-CAR T
HIV Viral Load at 3 Months Post-CAR T
HIV viral load measured at 3 months post CAR-T will be reported.
Time frame: 3 months post CAR-T
HIV Viral Load at 6 Months Post-CAR T
HIV viral load measured at 6 months post CAR-T will be reported.
Time frame: 6 months post CAR-T
HIV Viral Load at 9 Months Post-CAR T
HIV viral load measured at 9 months post CAR-T will be reported.
Time frame: 9 months post CAR-T
HIV Viral Load at 12 Months Post-CAR T
HIV viral load measured at 12 months post CAR-T will be reported.
Time frame: 12 months post CAR-T
Neutrophil Recovery
Neutrophil recovery is defined as when ANC is greater than or equal to 500 per mm3 achieved and sustained for 3 lab values. The number of participants who experience neutrophil recovery will be reported.
Time frame: 12 months after CAR-T
Platelet Recovery
Platelet recovery is defined as when platelet counts are greater than or equal to 20x10\^9 per L. The number of participants who experience platelet recovery will be reported.
Time frame: 12 months after CAR-T
Overall Survival
Overall survival is defined as the elapsed time between HCT and the date of death.
Time frame: Up to 2 years
Progression-free Survival
Progression-free survival is defined as elapsed time between HCT and disease progression or death from any cause. If a participant receives subsequent HCT, this participant will be censored as date of subsequent HCT.
Time frame: Up to 2 years
| Milestone | Observational |
|---|---|
| Started | 35 |
| Completed | 35 |
| Not completed | 0 |
Toxicities related to CAR19 therapy will be reported by Common Terminology for Adverse Events (CTCAE) criteria, as well as American Society for Transplantation and Cellular Therapy (ASTCT) criteria (for cytokine release syndrome). Maximum neurotoxicity will be reported. Grade 1 indicates a mild adverse event; Grade 2 indicates a moderate adverse event; Grade 3 indicates a severe adverse event; Grade 4 indicates life-threatening adverse event; and Grade 5 indicates death.
| Participants | Observational |
|---|---|
| No neurotoxicity | 27 |
| Grade 1 | 0 |
| Grade 2 | 1 |
| Grade 3 | 3 |
| Grade 4 | 3 |
| Grade 5 | 0 |
| Not reported | 1 |
Overall response is defined as complete remission (CR) plus partial remission (PR) based on response assessment using the Lugano criteria.
| percentage of participants with CR/PR | Observational |
|---|---|
| At 3 months | 40 (24.4 to 57.8) |
| At 6 months | 40 (24.4 to 57.8) |
Complete remission is defined as complete disappearance of all disease based on response assessment using the Lugano criteria.
| percentage of participants with CR | Observational |
|---|---|
| Complete Remission | 31.4 (17.4 to 49.4) |
CD8 count measured at 3 months post CAR-T will be reported
| cells/uL | Observational |
|---|---|
| CD8 Count at 3 Months Post CAR-T | 314 (48 to 1704) |
CD8 count measured at 6 months post CAR-T will be reported.
| cells/uL | Observational |
|---|---|
| CD8 Count at 6 Months Post CAR-T | 678 (113 to 1605) |
CD8 count measured at 9 months post CAR-T will be reported.
| cells/uL | Observational |
|---|---|
| CD8 Count at 9 Months Post-CAR T | 1016 (70 to 1452) |
CD8 count measured at 12 months post CAR-T will be reported.
| cells/uL | Observational |
|---|---|
| CD8 Count at 12 Months Post-CAR T | 1157 (65 to 1617) |
HIV viral load measured at 3 months post CAR-T will be reported.
| copies per mL | Observational |
|---|---|
| HIV Viral Load at 3 Months Post-CAR T | 10 (0 to 59) |
HIV viral load measured at 6 months post CAR-T will be reported.
| copies per mL | Observational |
|---|---|
| HIV Viral Load at 6 Months Post-CAR T | 26.5 (0 to 53) |
HIV viral load measured at 9 months post CAR-T will be reported.
| copies per mL | Observational |
|---|---|
| HIV Viral Load at 9 Months Post-CAR T | 60 (53 to 582000) |
HIV viral load measured at 12 months post CAR-T will be reported.
| copies per mL | Observational |
|---|---|
| HIV Viral Load at 12 Months Post-CAR T | 10 (0 to 178000) |
Neutrophil recovery is defined as when ANC is greater than or equal to 500 per mm3 achieved and sustained for 3 lab values. The number of participants who experience neutrophil recovery will be reported.
| Participants | Observational |
|---|---|
| Neutrophil Recovery | 28 |
Platelet recovery is defined as when platelet counts are greater than or equal to 20x10\^9 per L. The number of participants who experience platelet recovery will be reported.
| Participants | Observational |
|---|---|
| Platelet Recovery | 4 |
Overall survival is defined as the elapsed time between HCT and the date of death.
| percentage of participants | Observational |
|---|---|
| Overall survival at 100 days | 74.3 (58.7 to 87.2) |
| Overall survival at 6 months | 54.3 (37.8 to 70.3) |
| Overall survival at 1 year | 51.1 (34.7 to 67.4) |
| Overall survival at 2 years | 38.9 (20.8 to 58.8) |
Progression-free survival is defined as elapsed time between HCT and disease progression or death from any cause. If a participant receives subsequent HCT, this participant will be censored as date of subsequent HCT.
| percentage of participants | Observational |
|---|---|
| Progression-free survival at 100 days | 50 (31.9 to 68.1) |
| Progression-free survival at 6 months | 42.9 (25.4 to 61.3) |
| Progression-free survival at 1 year | 35.7 (19.3 to 54) |
| Progression-free survival at 2 years | 28.6 (12 to 48.8) |
Collected over Up to 2 years after CAR-T for mortality and 12 months after CAR-T for cytokine release syndrome (CRS) and neurotoxicity.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Observational | 19/35 (54.3%) | 0/35 (0%) | 24/35 (68.6%) |
| Event | Observational |
|---|---|
| Cytokine release syndromBlood and lymphatic system disorders | 24/35 |
| NeurotoxicityNervous system disorders | 8/35 |
| Age, Continuous(years) | Observational |
|---|---|
| Median | 56 (28.6 to 69.4) |
| Age, Customized(Participants) | Observational |
|---|---|
| 20-29 years | 2 |
| 30-39 years | 7 |
| 40-49 years | 6 |
| 50-59 years | 9 |
| 60-69 years | 11 |
| Sex: Female, Male(Participants) | Observational |
|---|---|
| Female | 4 |
| Male | 31 |
| Ethnicity (NIH/OMB)(Participants) | Observational |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 26 |
| Unknown or Not Reported | 3 |
| Race (NIH/OMB)(Participants) | Observational |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 9 |
| White | 20 |
| More than one race | 0 |
| Unknown or Not Reported | 6 |
| Region of Enrollment(participants) | Observational |
|---|---|
| United States | 35 |
| Disease type(Participants) | Observational |
|---|---|
| DLBCL | 32 |
| Follicular, predominantly small cleaved cell | 1 |
| Mantle cell Lymphoma | 1 |
| Follicular, predominantly large cell, grade IIIB | 1 |
| Karnofsky/Lansky performance score prior to CAR-T(Participants) | Observational |
|---|---|
| 90-100 | 17 |
| 80 | 9 |
| <80 | 9 |
15 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2021 to primary completion in Nov 2024, 41 months.
Results were first posted in Oct 2026, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
AIDS Malignancy Consortium